MARKET

ATYR

ATYR

Atyr Pharma Inc
NASDAQ
0.8990
+0.0883
+10.89%
After Hours: 0.8800 -0.019 -2.11% 19:58 02/06 EST
OPEN
0.8289
PREV CLOSE
0.8107
HIGH
0.9219
LOW
0.8163
VOLUME
1.63M
TURNOVER
--
52 WEEK HIGH
7.29
52 WEEK LOW
0.6400
MARKET CAP
88.09M
P/E (TTM)
-1.0772
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 3d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: aTyr Pharma (ATYR), Pfizer (PFE) and Bicycle Therapeutics (BCYC)
TipRanks · 3d ago
aTyr Pharma to meet FDA in April to discuss lead asset
Seeking Alpha · 4d ago
aTyr Pharma announces U.S. FDA accepted meeting request for efzofitimod
TipRanks · 4d ago
ATYR PHARMA INC - TYPE C MEETING SCHEDULED FOR MID-APRIL 2026
Reuters · 5d ago
Weekly Report: what happened at ATYR last week (0126-0130)?
Weekly Report · 6d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 01/29 12:05
Weekly Report: what happened at ATYR last week (0119-0123)?
Weekly Report · 01/26 09:10
More
About ATYR
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).

Webull offers aTyr Pharma Inc stock information, including NASDAQ: ATYR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATYR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATYR stock methods without spending real money on the virtual paper trading platform.